Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells

Molecular targeted compounds are emerging as a strategy to improve classical chemotherapy. Herein, we describe that using low dose of the multikinase inhibitor sorafenib improves cyclophosphamide antitumor activity by inhibiting angiogenesis, metastasis and promoting tumor healing in MDA-MB231 xenog...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Lett
Main Authors: Zanotto-Filho, Alfeu, Rajamanickam, Subapriya, Loranc, Eva, Masamsetti, Pragathi, Gorthi, Aparna, Romero, July Carolina, Tonapi, Sonal, Gonçalves, Rosangela Mayer, Reddick, Robert L., Benavides, Raymond, Kuhn, John, Chen, Yidong, Bishop, Alexander J. R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5930000/
https://ncbi.nlm.nih.gov/pubmed/29608984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2018.03.037
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados